Mobile website
Archive > Volume 24 Issue 8 > 2017,24(8):900-903. DOI:10.3872/j.issn.1007-385X.2017.08.015 Prev Next
Clinical Research
Expression and significance of RNA-binding protein 38 and p53 gene in lung adenocarcinoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To observe the mRNA and protein expressions of RNA-binding motif protein 38 (RBM38 or RNPC1) and tumor suppressor gene p53 in lung adenocarcinoma tissues, and to explore its significance in the occur-rence and development of lung adenocarcinoma. Methods: Tumor tissue samples from 50 lung adenocarcinoma pa-tients that treated in Affiliated Tumor Hospital of Xinjiang Medical University were selected as the experiment group, and the corresponding adjacent tissue samples were taken as the control group. The relative mRNA expres-sion of RBM38 and p53 in two groups were detected by RT-PCR method, and the relative protein expression of RBM38 and p53 were detected by Western blotting. Results: The mRNA and protein expressions of of RBM38 in the experimental group (0.357±0.170, 0.294±0.149) were higher than those of the control group (0.271±0.128,0.206±0.099), and the mRNA and protein expressions of p53 (0.457±0.208, 0.671±0.200) were higher than those of control group (0.308±0.167, 0.332±0.071); The difference was statistically significant (all P < 0.01). RBM38 expres-sion was related to TNM stage and depth of invasion in patients with lung adenocarcinoma (P < 0.05). The expres-sion of p53 was related to the TNM staging of the patients (P<0.05). The expression of RBM38 and p53 protein in the experience group were correlated (r=- 0.626, P<0.01). Conclusion: The mRNA and protein expressions of RBM38 and p53 in lung adenocarcinoma tissues were higher than that in adjacent tissues, and they were closely re-lated to the pathological parameters of the patients, such as TNM staging. With the increase of RBM38 protein ex-pression and decrease of p53 protein, RBM38 may promote the occurrence and development of lung cancer by in-hibiting the translation of p53. RBM38 may be the target of molecular targeted therapy for lung adenocarcinoma.
Keywords:
Project Supported:
Project supported by the National Natural Science Foundation of China (No. 81460354)
Clc Number:
